Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody : The First in an Emerging Class of Immunomodulatory Antibodies for Cancer TreatmentFONG, Lawrence; SMALL, Eric J.Journal of clinical oncology. 2008, Vol 26, Num 32, pp 5275-5283, issn 0732-183X, 9 p.Article

Sipuleucel-T (APC8015) for prostate cancerSO-ROSILLO, Rosendo; SMALL, Eric J.Expert review of anticancer therapy. 2006, Vol 6, Num 9, pp 1163-1167, issn 1473-7140, 5 p.Article

Immunotherapy for prostate cancerFONG, Lawrence; SMALL, Eric J.Seminars in oncology. 2003, Vol 30, Num 5, pp 649-658, issn 0093-7754, 10 p.Article

The case for secondary hormonal therapies in the chemotherapy ageSMALL, Eric J; RYAN, Charles J.The Journal of urology. 2006, Vol 176, Num 6, issn 0022-5347, S66-S71, 2Article

Early versus delayed androgen deprivation for prostate cancer : New fuel for an old debateRYAN, Charles J; SMALL, Eric J.Journal of clinical oncology. 2005, Vol 23, Num 32, pp 8225-8231, issn 0732-183X, 7 p.Article

A Phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinomaRINI, Brian I; WEINBERG, Vivian; SMALL, Eric J et al.Cancer. 2005, Vol 103, Num 3, pp 553-558, issn 0008-543X, 6 p.Article

Practice and progress in kidney cancer: Methodology for novel drug developmentRINI, Brian I; WEINBERG, Vivian; SMALL, Eric J et al.The Journal of urology. 2004, Vol 171, Num 6, pp 2115-2121, issn 0022-5347, 7 p., 1Article

High risk biochemical relapse and the timing of androgen deprivation therapyRYAN, Charles J; SMALL, Eric J.The Journal of urology. 2006, Vol 176, Num 6, issn 0022-5347, S61-S65, 2Article

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinomaRINI, Brian I; SMALL, Eric J.Journal of clinical oncology. 2005, Vol 23, Num 5, pp 1028-1043, issn 0732-183X, 16 p.Article

Osteoporosis in men treated with androgen deprivation therapy for prostate cancerROSS, Robert W; SMALL, Eric J.The Journal of urology. 2002, Vol 167, Num 5, pp 1952-1956, issn 0022-5347Article

Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer : History and rationale : Anti-Angiogenic and Cytotoxic Targeted Systemic Therapy for High-Risk Prostate CancerRYAN, Charles J; LIN, Amy M; SMALL, Eric J et al.Urologic oncology. 2006, Vol 24, Num 3, pp 250-253, issn 1078-1439, 4 p.Article

Update on chemotherapy for advanced bladder cancerROSENBERG, Jonathan E; CARROLL, Peter R; SMALL, Eric J et al.The Journal of urology. 2005, Vol 174, Num 1, pp 14-20, issn 0022-5347, 7 p.Article

Intermittent chemotherapy for metastatic hormone refractory prostate cancerLIN, Amy M; RYAN, Charles J; SMALL, Eric J et al.Critical reviews in oncology/hematology. 2007, Vol 61, Num 3, pp 243-254, issn 1040-8428, 12 p.Article

Secondary hormonal manipulation of prostate cancerSMALL, Eric J; HARRIS, Katherine A.Seminars in urologic oncology. 2002, Vol 20, Num 3, pp 24-30, issn 1081-0943, SUP1Conference Paper

Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells : The status of cancer vaccine therapies in urologyLIN, Amy M; HERSHBERG, Robert M; SMALL, Eric J et al.Urologic oncology. 2006, Vol 24, Num 5, pp 434-441, issn 1078-1439, 8 p.Article

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancerRINI, Brian I; WEINBERG, Vivian; BOK, Robert et al.Journal of clinical oncology. 2003, Vol 21, Num 1, pp 99-105, issn 0732-183X, 7 p.Article

Role of secondary hormonal therapy in the management of recurrent prostate cancerRYAN, Charles J; SMALL, Eric J.Urology (Ridgewood, NJ). 2003, Vol 62, Num 6B, pp 87-94, issn 0090-4295, 8 p.Article

Clinical trials in patients with biochemically relapsed prostate cancerLIN, Amy M; RINI, Brian I; SMALL, Eric J et al.BJU international (Papier). 2006, Vol 97, Num 5, pp 905-910, issn 1464-4096, 6 p.Article

PC-SPES and prostate cancerOH, William K; SMALL, Eric J.Urologic clinics of North America. 2002, Vol 29, Num 1, issn 0094-0143, viii, 59-66 [8 p.]Article

Complementary and alternative therapies in prostate cancerOH, William K; SMALL, Eric J.Seminars in oncology. 2002, Vol 29, Num 6, pp 575-584, issn 0093-7754, 10 p.Article

The impact of Prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: A pooled analysis of 9 Cancer and Leukemia Group B trialsHALABI, Susan; VOGELZANG, Nicholas J; OU, San-San et al.The Journal of urology. 2007, Vol 177, Num 2, pp 531-534, issn 0022-5347, 4 p.Article

Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancerHALABI, Susan; OU, San-San; VOGELZANG, Nicholas J et al.Cancer. 2007, Vol 110, Num 7, pp 1478-1484, issn 0008-543X, 7 p.Article

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)RATHKOPF, Dana E; SMITH, Matthew R; BEER, Tomasz M et al.European urology. 2014, Vol 66, Num 5, pp 815-825, issn 0302-2838, 11 p.Article

Efficacy of Peripheral Androgen Blockade in Prostate Cancer Patients With Biochemical Failure After Definitive Local Therapy: Results of Cancer and Leukemia Group B (CALGB) 9782PAUL MONK, J; HALABI, Susan; SMALL, Eric J et al.Cancer. 2012, Vol 118, Num 17, pp 4139-4147, issn 0008-543X, 9 p.Article

A Phase 2 Study of Estramustine, Docetaxel, and Bevacizumab in Men With Castrate-Resistant Prostate Cancer: Results From Cancer and Leukemia Group B Study 90006PICUS, Joel; HALABI, Susan; KELLY, W. Kevin et al.Cancer. 2011, Vol 117, Num 3, pp 526-533, issn 0008-543X, 8 p.Article